List view / Grid view
How times change. Up to 15 years ago, you would be hard-pressed to find a drug discovery conference with a track dedicated to phenotypic approaches. The underpinning science was called high-content imaging or analysis, being mainly confined to academic drug discovery labs and a handful of pioneers in industry. but…
Scientists in the U.S. have developed a powerful imaging tool to more accurately reproduce visuals of the brain and investigate mechanisms that precede Alzheimer’s symptoms.
Approach could improve understanding of immune system recovery in people treated for HIV infection...
Researchers release open source software, connecting and building the neuroscience coding community...
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
A novel PET imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory bowel disease...
High-content assays using 3D objects, such as cysts or organoids, can be challenging from the perspectives of both image acquisition and image analysis.
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Introducing the Thermo Scientific™ CellInsight™ CX7 LZR High Content Analysis System: the only imaging and analysis platform for advanced performance in screening and analysis.
Researchers have developed a new form of microscopy that allows them to observe the formation and evolution of cell membrane focal adhesions…
In this issue the latest applications of molecular imaging in drug development are reviewed by Ben Burke and Steve Archibald and new horizons in 3D microscopy are explored by Dimitri Scholz and Karl Gaff.
In this issue: the positive impact of genomics on drug discovery, development and deployment, the confluence of biology and technology, and Artificial Intelligence: harnessing the potential to drive progress in drug discovery promises much for phenotypic drug discovery
How to perform successful long term live cell imaging in a high-content analysis system.
The NIH is supporting efforts to broaden biomedical scientists’ access to cryo-electron microscopy the imaging method that is revolutionising structural biology...
